+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Gemcitabine-based chemotherapy for non-small cell lung cancer (NSCLC)--a review of 30 randomized trials



Gemcitabine-based chemotherapy for non-small cell lung cancer (NSCLC)--a review of 30 randomized trials



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 29(9): 1583-1596



Non-small cell lung cancer (NSCLC) represents a major challenge to oncologists because of its dismal outcomes. Conventional cytotoxic therapies for advanced disease have been unsatisfactory with modest efficacy and high toxicities. The last decade witnessed the introduction of many novel agents with enhanced efficacy and more manageable safety profile than conventional therapies. Gemcitabine is one of these novel agents which was introduced in the mid 1990's in the US/Europe and has been available in Japan since 1999. Due to its unique profile of great efficacy, mild toxicities and combinability with other agents, gemcitabine and its combination have been widely accepted as one of the standard regimens for the treatment of advanced NSCLC. There were multiple clinical trials demonstrated the superiority of gemcitabine or its combination over conventional therapies, especially in terms of increased response, prolonged survival, and quality of life enhancement for these patients. The current review presents an overview of all the randomized clinical trials of gemcitabine and its combination for advanced NSCLC published over the last decade.

(PDF emailed within 1 workday: $29.90)

Accession: 046152317

Download citation: RISBibTeXText

PMID: 12355944


Related references

Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trials. Journal of Clinical Oncology 23(16_suppl): 7213-7213, 2016

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. British Journal of Cancer 83(4): 447-453, 2000

Prognostic value of class III b-tubulin (TUBB3) in operable non-small cell lung cancer (NSCLC) and predictive value for adjuvant cisplatin-based chemotherapy (CT): A validation study on three randomized trials. Journal of Clinical Oncology 26(15_suppl): 7506-7506, 2016

Single-agent pemetrexed or sequentially administered pemetrexed/gemcitabine as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) in elderly patients or patients ineligible for platinum-based chemotherapy: Preliminary results of a phase II randomized trial. Journal of Clinical Oncology 23(16_suppl): 7156-7156, 2016

Sequencing of single-agent (SA) docetaxel (T) and gemcitabine (G) therapy for patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of three consecutive randomized trials. Journal of Clinical Oncology 24(18_suppl): 7035-7035, 2016

A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC). Lung Cancer 57(2): 168-174, 2007

Phase II trial with carboplatin/gemcitabine induction chemotherapy followed by radiotherapy concomitantly with paclitaxel/gemcitabine in stage III non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 24(18_suppl): 7139-7139, 2016

Paclitaxel and gemcitabine vs carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 23(16_suppl): 7000-7000, 2016

Randomized phase II study of gemcitabine-oxaliplatin or gemcitabine-cisplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC)-CLEO 05. Journal of Clinical Oncology 24(18_suppl): 7097-7097, 2016

Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study. Lung Cancer 55(2): 173-180, 2006

Randomized phase II cross-over sequential chemotherapy trial of irinotecan/cisplatin (IP) vs. gemcitabine/vinorelbine (GV) in chemo-naïve patients with stage IIIb/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 24(18_suppl): 7134-7134, 2016

A randomized phase II study of gemcitabine (G) vs gemcitabine/carboplatin (GC) as consolidation therapy to concurrent chemoradiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC): A Lung Cancer Research Group (LCRG) study. Journal of Clinical Oncology 26(15_suppl): 7559-7559, 2016

ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p). Journal of Clinical Oncology 23(16_suppl): 7002-7002, 2016

Phase II trial with carboplatin/gemcitabine (Cb/G) induction chemotherapy (CT) followed by radiotherapy concomitantly with paclitaxel/gemcitabine (P/G) in stage III non small cell lung cancer (NSCLC): Preliminary report. Journal of Clinical Oncology 23(16_suppl): 7122-7122, 2016

Paclitaxel, carboplatin, and gemcitabine (PCG) versus gemcitabine and vinorelbine (GV) in chemotherapy naïve patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase III trial of the Minnie Pearl Cancer Research Network (MPCRN). Journal of Clinical Oncology 23(16_suppl): 7056-7056, 2016